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Background: To better characterize short and long-term outcomes in children with 
pancreatic tumors treated with pancreaticoduodenectomy (PD). 
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Methods: Patients 21 years of age or younger who underwent PD at Pediatric Surgical 
Oncology Collaborative (PSORC) hospitals between 1990-2017 were identified. 
Demographic, clinical information and outcomes (operative complications, long-term 
pancreatic function, recurrence, and survival) were collected. 
 
Results: Sixty-five patients from 18 institutions with a median age of 13 years (4 months 
– 22 years) and a median (IQR) follow up of 2.8 (4.3) years were analyzed. Solid 
pseudopapillary tumor of the pancreas (SPN) was the most common histology. 
Postoperative complications included pancreatic leak in 14% (n=9), delayed gastric 
emptying in 9% (n=6), marginal ulcer in 1 patient, and perioperative (30-day) death 
due to hepatic failure in 1 patient. Pancreatic insufficiency was observed in 32% (n=21) 
of patients, with 23%, 3%, and 6% with exocrine, or endocrine insufficiencies, or both, 
respectively. Children with SPN and benign neoplasms all survived. Overall, there were 
14 (22%) recurrences and 11 deaths (17%). Univariate analysis revealed non-SPN 
malignant tumor diagnosis, preoperative vascular involvement, intraoperative 
transfusion requirement, pathologic vascular invasion, positive margins, and need for 
neoadjuvant chemotherapy as risk factors for recurrence and poor survival.  
Multivariate analysis only revealed pathologic vascular invasion as a risk factor for 
recurrence and poor survival. 
 
Conclusion: This is the largest series of pediatric PD patients.PD is curative for SPN and 
benign neoplasms. Pancreatic insufficiency is the most common postoperative 
complication. Outcome is primarily associated with histology. 
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Introduction 
Pancreatic tumors are an uncommon diagnosis amongst children, with an incidence of 
pancreatic malignancies in children of only0.018 per 100,000 in the US, compared to 
12.6 per 100,000 adults1,2. Pancreatic neoplasms requiring pancreaticoduodenectomy 
(PD) in children are even more rare3. Literature on short and long-term outcomes after 
PD in children is very limited4. Due to the low incidence of PD being performed at any 
one institution, a multi-institutional retrospective review of children undergoing PD 
was initiated through the Pediatric Surgical Oncology Research Collaborative (PSORC), a 
multi-institutional collaborative with the aim of furthering research in pediatric surgical 
oncology. The purpose of this study was to perform a comprehensive analysis of 
children with pancreatic tumors undergoing PD with a focus on preoperative 
evaluation, operative technique, perioperative care, and short- and long-term 
complications to better understand the perioperative problems, and to ultimately 
improve the surgical care of these patients. 
 
Methods 
Patients 21 years of age or younger who underwent PD for pancreatic tumors at PSORC 
member institutions between 1990-2017 were identified. Demographic, clinical 
information and outcomes (operative complications, long-term pancreatic function, 
recurrence, and survival) were retrospectively extracted from medical records. 
Operative complications were all defined and diagnosed by each member institution’s 
surgeon and treatment team. Short-term complications (pancreatic leak, marginal ulcer, 
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perioperative death, gastroduodenal artery bleed, and biliary stricture) were all defined 
clinically.Long-term complications (exocrine, endocrine pancreatic insufficiency, and 
delayed gastric emptying) were defined as requiring medical or surgical intervention. 
Specifically, exocrine insufficiency was defined as requiring prolonged pancreatic 
enzymes. Endocrine insufficiency was defined as requiring anti-hyperglycemics or 
insulin. Vitamin deficiency was defined as requring fat soluble vitamin (A, D, E, or K) 
supplementation. Statistical analyses, performed by an outcomes statistician at Texas 
Children’s Hospital who is the third author of this study, included Fisher’s exact and 
Mann Whitney tests when appropriate. Univariate log rank/cox modeling and 
multivariate cox modeling were used to analyze correlations with recurrence and 
survival. Results were considered significant at a P value of <0.05. This study was 
approved by each participating PSORC member institution’s review board. Data use 
agreements between all participating PSORC member institutions and the lead 
institution for this study were established. 
 
Results 
Demographics and clinical characteristics 
Sixty-five children from 18 institutions who underwent PD for treatment of pancreatic 
tumors were identified. Within the 27-year period, each hospital reported a median of 
2.5 cases (range 1- 15 cases). The demographic, diagnostic, and treatment 
characteristics are summarized in Table 1. The median age at diagnosis was 13 years 
(range 4 months – 21 years) and the majority of patients were Caucasian.  Underlying 
genetic abnormalities identified in the cohort include Beckwith-Wiedemann syndrome 
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and Lynch syndrome, each in two patients.The most common diagnosis was solid 
pseudopapillary tumor of the pancreas (SPN) (n=34, 52%) (Table 2). Preoperative 
diagnostic evaluation included endoscopic ultrasound (EUS) biopsy (n=18, 28%), cross-
sectional imaging alone (n=15, 23%), open biopsy (n=10, 15%), percutaneous biopsy 
(n=7, 11%), with the remainder (n=15, 23%) being unspecified. Of the patients later 
found to have SPN after surgical resection, 19 (56%)underwent a pre-operative biopsy. 
Data regarding whether percutaneous biopsy was FNA at the time of EUS versus core 
needle biopsy was not recorded. All patients underwent advanced imaging.The 
presence or absence of preoperative biopsy (including EUS biopsy, open biopsy, and 
percutaneous biopsy) had no significant association withpostoperative complications, 
recurrence, or death(p>0.5). Twenty-three percent (n=15) of patients showed tumor 
involvement of either the superior mesenteric artery (SMA), superior mesenteric vein 
(SMV), portal vein, and/or middle colic artery on preoperative workup, of whom 67% 
(n=10) had non-SPN malignant tumors. 
Treatment 
All patients underwent open PD.  An adult hepatobiliary surgeon assisted with or 
performed the PD in 34% of the cases (n=22). A pylorus-preserving PD (63%) with a 
perianastomotic drain (68%) was the most common procedure performed. Two 
patients underwent vascular reconstruction. Both of these patients had 
pancreaticoblastoma. One patient underwent a portal vein reconstruction because a 
tumor thrombus was found in the portal vein. The other patient underwent portal vein 
and hepatic artery reconstruction because tumor was encasing the portal vein, hepatic 
artery, and superior mesenteric vein. None of the patients with SPN underwent 
neoadjuvant or adjuvant chemotherapy. Data regarding the specific neoadjuvant and 
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adjuvant chemotherapy regimens were not recorded in this study.Twenty-nine percent 
(n=19) and 12% (n=8) of patients received an intraoperative or postoperative packed 
red blood cell (PRBC) transfusion, respectively. Sixty-nine percent (n=45) of patients 
required ICU care postoperatively. The median hospital length of stay was 12 days (3-56 
days). Positive margins and vascular invasion on histology were found in 9 (14%) and 
14 (22%) patients, respectively.  
Complications 
Short-term postoperative complications (Table 3) were defined as complications 
persisting less than 30 days after PD and included pancreatic leak in 14% of patients 
(n=9), marginal ulcer in 1 patient (2%), and perioperative death due to hepatic failure 
in 2% of patients (n=1). No patient suffered from gastroduodenal bleeding or biliary 
stricture postoperatively. For short-term postoperative complications, Clavien-Dindo 
grades I (n=1), II (n=2), III (n=2), and V (n=1) were present5. Long-term postoperative 
complications (Table 4) were defined as complications at 1 year or greater after PD and 
included pancreatic insufficiency in 21 patients (32%), delayed gastric emptying in 6 
patients (9%), and vitamin deficiencies in 3 patients (5%). For long-term postoperative 
complications, Clavien-Dindo grades II (n=4) and III (n=1) were present5. No risk 
factors for pancreatic leak were identified while longer operative times and ICU length 
of stays were associated with long-term complications (Supplementary table 1). 
Outcomes 
The median (IQR) follow-up was 2.8 years (4.3 years). Overall, 28% of patients (n=18) 
had over 5 years of follow-up. Five percent of patients (n=2) developed a second 
malignancy. One patient with Lynch syndrome who underwent PD for duodenal 
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adenocarcinoma later developed both colon and breast adenocarcinoma, and another 
patient who underwent PD for pancreatic neuroblastoma later developed 
dermatofibrosarcoma protuberans. Children with SPN and benign neoplasms all 
survived. Out of the patients with SPN, positive margins and vascular invasion on 
histology were both found 2 patients (6%). The remainder of the patients with SPN had 
negative margins and no vascular invasion on pathology. Of the patients with SPN, only 
1 patient (3%) had recurrence. The patient with SPN who had recurrence had positive 
margins and vascular invasion on pathology. Overall, there were 14 (22%) recurrences 
(Figure 1) with 11 deaths (17%) (Figure 2).  The median time to recurrence from date 
of PD was 1.5 years (46 days – 4.4 years).  Significant risk factors for recurrence on 
univariate analyses included need for neoadjuvant chemotherapy, preoperative 
vascular involvement, non-SPN malignant tumor, intraoperative transfusion 
requirement, pathologic vascular invasion, and positive margins (Supplementary table 
2). Similarly, significant risk factors for death on univariate analyses also included need 
for neoadjuvant chemotherapy, preoperative vascular involvement, non-SPN malignant 
tumor, intraoperative transfusion requirement, pathologic vascular invasion, and 
positive margins (Supplementary table 2). Vascular invasion on pathology (HR=8.293, 
CI=1.101– 62.460, p=0.0400; HR=11.235, CI=1.052 -120.025, p=0.0453) was found to 
be an independent predictor of both recurrence and death on multivariate analyses 
(Supplementary table 3). Neither recurrence nor survival was impacted by age, race, 
operative time, insurance status, preoperative comorbidities, presence of an 
hepatobiliary surgeon specializing in care of adults, type of PD, type of 
pancreaticojejunostomy, use of stents or use of drains.  
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Discussion 
Pancreaticoduodenectomy, also known as the Whipple procedure, is the gold standard 
for surgical treatment of pancreatic malignancies involving the head of the pancreas in 
adults6,7. However, due to the rarity of pancreatic neoplasms in children, reports on 
outcomes of PD in children are limited. We utilized the PSORC to identify and examine 
65 patients at 18 different institutions to enrich the literature on outcomes and 
complications of PD in children. 
Cross-sectional imaging alone, including CT and/or magnetic resonance imaging (MRI), 
was used for preoperative diagnostic evaluation in 15 children in our study. MRI is often 
used in children due to the risks of radiation exposure with high resolution CT and 
better tissue characterization to detect occult lesions.8,9,10.  Endoscopic ultrasound 
(EUS) biopsy (n=18) was most commonly used for preoperative diagnostic evaluation in 
our study. Overall, EUS was utilized during preoperative workup in 20 children.A study 
performed by Law et al showed an increase in diagnostic accuracy from 24% with CT 
alone to 82% with the addition of EUS with fine needle aspiration (FNA) for the 
diagnosis of SPN11.  We did not collect data on the diagnostic accuracy of FNA versus 
core needle biopsy.  However, a study showed that FNA could be 100% diagnostic for 
SPN with detection of the CTNNB1 (-catenin) mutation12.  This study was not 
performed in children specifically but could be a viable approach to diagnosing SPN.   
In our study, 10 patients underwent open biopsy and 7 patients underwent 
percutaneous biopsy. The utility in obtaining a preoperative biopsy in children would 
be to distinguish between SPN and other malignant pathologies.In the Nasheret al study, 
children with pancreatic tumors (n=14) all had preoperative transabdominal 
ultrasound and CT scans and only 1 patient underwent a pre-excisional biopsy13. All 
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children had complete surgical resection of the pancreatic mass and the authors 
concluded that the majority of children with pancreatic tumors are good surgical 
candidates since they present with isolated lesions13. 
The most common overall histologic diagnosis was SPN. Similar to previous studies, the 
most common pancreatic malignancy in younger children (10 years, range 4 – 18 years) 
was pancreatoblastoma while that in older children (14 years, range 8 – 19 years) was 
SPN2,14–17. SPN does have a typical appearance on MRI and does not require sampling to 
confirm; however, differentiating the diagnosis of pancreatoblastoma from SPN can be 
challenging without an elevation in alpha fetoprotein (AFP)18.  The pathognomonic 
squamoid corpuscles of pancreatoblastoma would only be visible on histology; 
therefore, sampling of the tumor may be of value when this diagnosis is suspected so 
that neoadjuvant chemotherapy can be used to reduce the tumor size prior to surgery19. 
SPN is a low-grade malignancy with minimal metastatic potential, and multiple other 
studies have likewise reported excellent prognosis after resection14,16,20,21. 
While a diagnosis of non-SPN malignant tumor was found to be a risk factor for both 
recurrence and death, children with SPN all survived and only one child with SPN had 
recurrence in this study. The patient with recurrence originally underwent enucleation 
of a pancreatic head SPN at an outside hospital. The enucleated mass had positive 
margins. This patient then presented with recurrent pancreatic head SPN and 
underwent a PD at a PSORC institution and had no recurrence after PD. Enucleation is a 
technique that can be used for SPN pathology in a subgroup of patients with the proper 
anatomic relations22-26.  A head of the pancreas mass is usually very close to the portal 
vein/SMV, bile duct, and pancreatic duct; therefore successful enucleation with a 
negative margin may not be possible.  A few studies have reported enucleation in 
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children with SPN where positive margins seem to be associated with recurrence20,21,27.  
These results collectively suggest that negative margin resection should be the goal of 
surgical resection for SPN since adjuvant therapy is currently not recommended. 
The majority of our patients underwent pylorus-preserving PD. We found that there 
was no significant difference in short- or long-term complications, recurrence, or death 
between patients who underwent pylorus-preserving PD versus non-pylorus-
preserving PD similar to what is seen in adults28. Duct-to-mucosa and sock-type 
pancreaticojejunostomies were performed at equal rates in our study. The type of 
pancreaticojejunostomy had no significant difference in short- or long-term 
complications or death which was again consistent with adult literature29. Most of our 
patients had a perianastomotic drain placed.  The presence or absence of a drain had no 
significant effect on the short- or long-term complications or death. The majority of 
patients with SPN in our study did not undergo chemotherapy. 
Twenty-nine percent (n=19) of patients received an intra-operative PRBC transfusion, 
with a median of 2 PRBC units (0.5 - 8 PRBC units). Intraoperative PRBC transfusion 
was found to be a significant risk factor for both death and recurrence on univariate 
analysis.  Although an association between PRBC transfusion and outcomes in children 
after PD has not been established, this association has been shown in adults. Yeh et al 
and Kneuertzet al both found perioperative PRBC transfusion to be an independent 
predictor of recurrence and death after PD in adults30,31. However, our study differs 
from these studies in that intraoperative, but not postoperative, transfusion of PRBC 
was found to be significantly associated with recurrence (p=0.045) and survival 
(p=0.0017). While the definitive mechanism behind the impact of PRBC transfusion on 
disease recurrence and death is currently unknown, intraoperative transfusion 
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requirement may be a proxy for the proximity of the tumor to major vessels, thus 
rendering the achievement of negative margins more technically challenging. This may 
explain why PRBC transfusion was not an independent risk factor for recurrence or 
death. 
The most common short-term postoperative complication was pancreatic leak, found in 
14% (n=9) of our patients. Lindholm et al and Choi et al reported pancreatic leak rates 
at 8% (n=1) and 9% (n=2) in children after PD, respectively14,17. The mean and standard 
deviation operative times for patients in this study with and without pancreatic leak 
were 476 ± 201 and 374 ± 188 minutes, respectively, although this was not statistically 
significant (p=0.14). We found that preoperative comorbidities, need for neoadjuvant 
chemotherapy, assistance by an adult hepatobiliary surgeon, type of 
pancreaticojejunostomy anastomosis, peri-anastomotic drain, postoperative 
chemotherapy, and postoperative radiation were not associated with pancreatic leak. 
Additionally, non-SPN malignant diagnoses had a similar rate of short-term 
postoperative complications compared to the SPN and benign group. 
Long-term postoperative complications included delayed gastric emptying, vitamin, and 
pancreatic deficiencies. Notably, 42% of patients in our study had some form of long-
term postoperative complication. The pancreatic insufficiency rate of 32% (n=21) is less 
than the reported rates of 60%-83% in the literature for children undergoing PD17,32.  
Additionally, of the patients with pancreatic insufficiency, 71% had exocrine 
insufficiency which were all successfully treated with pancreatic enzyme 
supplementation. The finding of delayed gastric emptying in 9% (n=6) of patients is less 
than the 17% reportedby Lindholm et al (n=2)17. Of the 6 patients with delayed gastric 
emptying, only 1 underwent a pylorus preserving PD while the other 5 did not have a 
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pylorus preserving PD. Non-SPN malignant diagnoses also had a similar rate of long-
term postoperative complications compared to patients with SPN.  The association 
between presence of long-term complications and ICU length of stay is difficult to 
explain. We can only speculate that ICU length of stay is a proxy for more complex 
surgery and more extensive pancreatic resection leading to the eventual development of 
these complications. 
The recurrence and mortality rates in this series were 22% and 17%, respectively, 
during a median (IQR) follow up of 2.8 (4.3) years. Other studies of children who have 
undergone PD for pancreatic tumors reported a recurrence rate of 43% and mortality 
rates of 13% - 58%15,17,32. Perez et al concluded that survival for children with 
malignant pancreatic tumors is significantly greater for patients who have surgery 
compared to those who do not undergo surgical resection (p=0.001)2. The effect of PD 
volume at a single institution on the complication, recurrence, and survival rates could 
not be determined given that the median number of cases per institution was relatively 
low at 2.5 cases, with the number of total cases ranging from 1-15 (IQR 3) with 5 
institutions having only 1 case.   
There are several limitations to this study. The retrospective nature of this study 
invariably results in some missing data.Additionally, since this was a retrospective 
study, uniform criteria for postoperative complications were not defined in advance. 
The inclusion criteria for this study was broad andnot disease specific by necessity. 
Weaknesses include a lengthy study period of 27 years and the inclusion of a breadth of 
ages of children withvarying pathologies in the head of the pancreas requiring 
PD.Regardless of these limitations, a prospective study of PD in children will be unlikely 
due to the low number of cases in any one institution; however, we feel that this multi-
 
This article is protected by copyright. All rights reserved. 
center consortium approach has provided guidance on operative methods, expected 
complication rates, and outcomes of children undergoing PD for neoplasm.   
Conclusion 
PD can be performed safely in children for the treatment of pancreatic neoplasms. 
Pylorus-preserving PD with a peri-anastomotic drain is the most common procedure. 
Pancreatic leak and pancreatic exocrine insufficiency are the most common short-term 
and long-term postoperative complications, respectively. Outcomes in this study were 
primarily associated with histology. 
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Figure 1: Kaplan Meier curve for recurrence with 95% Hall-Wellner bands 
Red line = solid pseudopapillary tumor of the pancreas (SPN) diagnosis 
Blue line = malignant non-SPN diagnosis 
 





Figure 2: Kaplan Meier curve for death with 95% Hall-Wellner bands 
Red line = solid pseudopapillary tumor of the pancreas (SPN) diagnosis 
Blue line = malignant non-SPN diagnosis 
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Tables and Figures 
 
 
Table 1. Demographic, diagnostic, and treatment characteristics 











Age – median [range] 13 [0.33 – 22] y 




Von Willebrand disease 
Mixed connective tissue disease 
Sickle cell trait 
Pancreatic divisum 
Inflammatory bowel disease 
Chronic pancreatitis 
















Hepatitis C 1 (2) 
Hyper IgM syndrome 1 (2) 
Other 3 (5) 
Insurance  
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Private 33 (51) 
Uninsured 7 (11) 
Government 19 (29) 
Preoperative diagnostic method  
Endoscopic ultrasound biopsy 18 (28) 
Imaging only 15 (23) 
Open biopsy 10 (15) 
Percutaneous biopsy 7 (11) 
Unspecified 15 (23) 
Vascular involvement on preoperative 
diagnosis 
15 (23) 
Clear of vessels 50 (77) 
SMV only 6 (9) 
SMV and SMA 5 (8) 
Portal vein 2 (3) 
Portal vein, hepatic artery, SMV 1 (2) 
Middle colic artery 1 (2) 
Neoadjuvant chemotherapy 16 (25) 
Neoadjuvant radiation 7 (11) 
Adult hepatobiliary surgeon involved 22 (34) 
Open PD 65 (100) 
Pylorus-preserving PD 41 (63) 







Unspecified 3 (5) 
Pancreaticojejunostomy stent 9 (14) 
Hepaticojejunostomy stent 5 (8) 
Operative time – median [range] 7.2 [1.5 – 21.5] h 
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EBL – median [range] 250 [50 – 5,000] cc 
PRBC transfusion  
Intraoperative 19 (29) 
Median [range] 2 [0.5 – 8] PRBC u 
Postoperative 8 (12) 
Median [range] 1 [1 -7] PRBC u 
Postoperative antibiotics 49 (75) 
Postoperative mechanical ventilation 14 (22) 
Median [range) 1.5 [1-7] d 
Postoperative ICU  45 (69) 
Median [range] 2 [1-27] d 
Hospital LOS – median [range] 12 [3 – 56] d 
Positive margins on histology 9 (14) 
Vascular invasion on histology 14 (22) 
Adjuvant chemotherapy 17 (26) 
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Table 2. Histological diagnoses 
Histologic diagnosis Number of patients (%) 
SPN 34 (52) 
Benign neoplasm 3 (5) 
Malignant neoplasms 28 (43) 
Pancreatoblastoma 8 (12) 
Carcinoma 5 (8) 
Rhabdomyosarcoma 3 (5) 
Neuroblastoma 3 (5) 
Neuroendocrine 4 (6) 
Ewing sarcoma 2 (3) 
Anaplastic large cell lymphoma 1 (2) 







Table 3. Short-term postoperative complications < 30 days after PD  
Short-term 
complication 
Number of patients 
(%) 
Treatment (n) Clavien-Dindo 
Classification 
Pancreatic leak 9 (14) Surgical drain 
placement (6) 
III 
  Percutaneous drainage 
(1) 
III 
  Octreotide (1) II 
  Observation (1) I 
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Perioperative death  1 (2) -------------------- V 
Gastroduodenal artery 
bleed 
0 -------------------- -------------------- 














21 (32)   
Exocrine  15 (23) Pancrealipase (13) II 
Endocrine 2 () Insulin (2) II 





6 (9) Medical management (3) II 






Vitamin deficiency  3 (5) -------------------- -------------------- 
 
 
